Pfizer delays patent cliff for blockbuster Vyndamaxnews2026-04-28T17:36:36+00:00April 28th, 2026|Endpoints News|
Hikma and Amarin’s generic drug case heads to Supreme Court argumentsnews2026-04-28T17:14:57+00:00April 28th, 2026|Endpoints News|
Rocket’s PRV goes for $180M; Oruka targets $500M offeringnews2026-04-28T14:54:36+00:00April 28th, 2026|Endpoints News|
BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGFnews2026-04-28T14:42:57+00:00April 28th, 2026|Endpoints News|
Incyte claims double Phase 3 win in vitiligo, will file for approvalnews2026-04-28T14:36:35+00:00April 28th, 2026|Endpoints News|
Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrelnews2026-04-28T13:20:17+00:00April 28th, 2026|Endpoints News|
FDA claims trial ‘manipulation’ tainted approval of ChemoCentryx drugnews2026-04-28T13:09:24+00:00April 28th, 2026|Endpoints News|
Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage marketnews2026-04-28T13:00:55+00:00April 28th, 2026|Endpoints News|
Adaptyv Bio reveals latest results in protein design competitionnews2026-04-28T12:00:20+00:00April 28th, 2026|Endpoints News|
Lilly strikes second partnership this year for recombinase-based gene editingnews2026-04-28T11:00:57+00:00April 28th, 2026|Endpoints News|
